CASC3 and Miyoshi myopathy: This paper provides evidence that BTZ is efficacious in reducing the viability of HCT116 and HT29 colon cancer cells at a concentration range up to 15 nM, which is considerably lower compared to the corresponding plasma concentrations obtained in MM patients (Sogbein et al., 2024).